Storytelling Co – Lifestyle
Author:
Scynexis
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
May 6, 2026
SCYNEXIS Announces $40.0 Million Private Placement
March 31, 2026
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
March 31, 2026